Market Research Logo

Bladder and Ureter Cancer Drug Development Pipeline Review, 2017

Bladder and Ureter Cancer Drug Development Pipeline Review, 2017

Summary


Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. There are a total of 223 products in development for this indication, by 158 companies and 19 academic institutions. Key companies active in this space include F. Hoffmann-La Roche, GlaxoSmithKline, AstraZeneca, MedImmune and Pfizer.

Ureter or ureteral cancer affects the ureter, the tube that transports urine from the kidney to the urinary bladder. Symptoms and signs of the disease include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. There are a total of nine products in development for this indication, by six companies and two academic institutions.

These products act on a wide range of targets, including a number of growth factor receptors and intracellular signal transducers. Within bladder cancer, the most commonly developed targets are Programmed Cell Death 1 Ligand 1 and Tubulin.

The report “Bladder and Ureter Cancer Drug Development Pipeline Review, 2017” provides an overview of the bladder and ureter pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for these two indications, and features dormant and discontinued projects.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration


  • GBI Research Report Guidance
  • Executive Summary
  • Introduction
    • Bladder and Ureter Cancer Report Coverage
    • Ureter Cancer – Overview
    • Bladder Cancer – Overview
  • Therapeutics Development
    • Ureter Cancer
      • Pipeline Overview
        • Table Figure 1: Number of Products under Development for Ureter Cancer
        • Table Number of Products under Development for Ureter Cancer
      • Pipeline by Companies
        • Table Figure 2: Number of Products under Development by Companies, Ureter Cancer
        • Table Number of Products under Development by Companies, Ureter Cancer
      • Pipeline by Universities/Institutes
        • Table Figure 3: Number of Products under Development by Universities/Institutes, Ureter Cancer
        • Table Number of Products under Development by Universities/Institutes, Ureter Cancer
      • Products under Development by Companies
        • Table Products under Development by Companies, Ureter Cancer
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Ureter Cancer
    • Bladder Cancer
      • Pipeline Overview
        • Table Figure 4: Number of Products under Development for Bladder Cancer
        • Table Number of Products under Development for Bladder Cancer
      • Pipeline by Companies
        • Table Figure 5: Number of Products under Development by Companies, Bladder Cancer
        • Table Number of Products under Development by Companies, Bladder Cancer
      • Pipeline by Universities/Institutes
        • Table Figure 6: Number of Products under Development by Universities/Institutes, Bladder Cancer
        • Table Number of Products under Development by Universities/Institutes, Bladder Cancer
      • Products under Development by Companies
        • Table Products under Development by Companies, Bladder Cancer
      • Products under Development by Universities/Institutes
        • Table Products under Development by Universities/Institutes, Bladder Cancer
  • Therapeutics Assessment
    • Ureter Cancer
      • Assessment by Target
        • Table Figure 7: Number of Products by Top 10 Targets, Ureter Cancer
        • Table Figure 8: Number of Products by Stage and Top 10 Targets, Ureter Cancer
        • Table Number of Products by Stage and Target, Ureter Cancer
      • Assessment by Mechanism of Action
        • Table Figure 9: Number of Products by Top 10 Mechanism of Actions, Ureter Cancer
        • Table Figure 10: Number of Products by Stage and Top 10 Mechanism of Actions, Ureter Cancer
        • Table Number of Products by Stage and Mechanism of Action, Ureter Cancer
      • Assessment by Route of Administration
        • Table Figure 11: Number of Products by Routes of Administration, Ureter Cancer
        • Table Figure 12: Number of Products by Stage and Top 10 Routes of Administration, Ureter Cancer
        • Table Number of Products by Stage and Route of Administration, Ureter Cancer
      • Assessment by Molecule Type
        • Table Figure 13: Number of Products by Molecule Types, Ureter Cancer
        • Table Figure 14: Number of Products by Stage and Molecule Types, Ureter Cancer
        • Table Number of Products by Stage and Molecule Type, Ureter Cancer
    • Bladder Cancer
      • Assessment by Target
        • Table Figure 15: Number of Products by Top 10 Targets, Bladder Cancer
        • Table Figure 16: Number of Products by Stage and Top 10 Targets, Bladder Cancer
        • Table Number of Products by Stage and Target, Bladder Cancer
      • Assessment by Mechanism of Action
        • Table Figure 17: Number of Products by Top 10 Mechanism of Actions, Bladder Cancer
        • Table Figure 18: Number of Products by Stage and Top 10 Mechanism of Actions, Bladder Cancer
        • Table Number of Products by Stage and Mechanism of Action, Bladder Cancer
      • Assessment by Route of Administration
        • Table Figure 19: Number of Products by Routes of Administration, Bladder Cancer
        • Table Figure 20: Number of Products by Stage and Routes of Administration, Bladder Cancer
        • Table Number of Products by Stage and Route of Administration, Bladder Cancer
      • Assessment by Molecule Type
        • Table Figure 21: Number of Products by Top 10 Molecule Types, Bladder Cancer
        • Table Figure 22: Number of Products by Stage and Top 10 Molecule Types, Bladder Cancer
        • Table Number of Products by Stage and Molecule Type, Bladder Cancer
  • Companies Involved in Therapeutics Development
    • Ureter Cancer
      • Altor BioScience Corp
        • Table Ureter Cancer – Pipeline by Altor BioScience Corp
      • Eisai Co Ltd
        • Table Ureter Cancer – Pipeline by Eisai Co Ltd
      • Exelixis Inc
        • Table Ureter Cancer – Pipeline by Exelixis Inc
      • GlaxoSmithKline Plc
        • Table Ureter Cancer – Pipeline by GlaxoSmithKline Plc
      • MedImmune LLC
        • Table Ureter Cancer – Pipeline by MedImmune LLC
      • Merck & Co Inc
        • Table Ureter Cancer – Pipeline by Merck & Co Inc
    • Bladder Cancer
      • 4SC AG
        • Table Bladder Cancer – Pipeline by 4SC AG
      • Abivax SA
        • Table Bladder Cancer – Pipeline by Abivax SA
      • Adaptimmune Therapeutics Plc
        • Table Bladder Cancer – Pipeline by Adaptimmune Therapeutics Plc
      • ADC Therapeutics Sarl
        • Table Bladder Cancer – Pipeline by ADC Therapeutics Sarl
      • Altor BioScience Corp
        • Table Bladder Cancer – Pipeline by Altor BioScience Corp
      • AndroScience Corp
        • Table Bladder Cancer – Pipeline by AndroScience Corp
      • ANP Technologies Inc
        • Table Bladder Cancer – Pipeline by ANP Technologies Inc
      • APIM Therapeutics AS
        • Table Bladder Cancer – Pipeline by APIM Therapeutics AS
      • Archivel Farma SL
        • Table Bladder Cancer – Pipeline by Archivel Farma SL
      • Argos Therapeutics Inc
        • Table Bladder Cancer – Pipeline by Argos Therapeutics Inc
      • Arno Therapeutics Inc
        • Table Bladder Cancer – Pipeline by Arno Therapeutics Inc
      • Array BioPharma Inc
        • Table Bladder Cancer – Pipeline by Array BioPharma Inc
      • Asana BioSciences LLC
        • Table Bladder Cancer – Pipeline by Asana BioSciences LLC
      • Asieris Pharmaceuticals Co Ltd
        • Table Bladder Cancer – Pipeline by Asieris Pharmaceuticals Co Ltd
      • Astellas Pharma Inc
        • Table Bladder Cancer – Pipeline by Astellas Pharma Inc
      • Astex Pharmaceuticals Inc
        • Table Bladder Cancer – Pipeline by Astex Pharmaceuticals Inc
      • AstraZeneca Plc
        • Table Bladder Cancer – Pipeline by AstraZeneca Plc
      • AVEO Pharmaceuticals Inc
        • Table Bladder Cancer – Pipeline by AVEO Pharmaceuticals Inc
      • Bavarian Nordic A/S
        • Table Bladder Cancer – Pipeline by Bavarian Nordic A/S
      • Bayer AG
        • Table Bladder Cancer – Pipeline by Bayer AG
      • Biocad
        • Table Bladder Cancer – Pipeline by Biocad
      • BioCancell Ltd
        • Table Bladder Cancer – Pipeline by BioCancell Ltd
      • Biohaven Pharmaceutical Holding Company Ltd
        • Table Bladder Cancer – Pipeline by Biohaven Pharmaceutical Holding Company Ltd
      • Biomics Biotechnologies Co Ltd
        • Table Bladder Cancer – Pipeline by Biomics Biotechnologies Co Ltd
      • Biotest AG
        • Table Bladder Cancer – Pipeline by Biotest AG
      • Boehringer Ingelheim GmbH
        • Table Bladder Cancer – Pipeline by Boehringer Ingelheim GmbH
      • Bristol-Myers Squibb Co
        • Table Bladder Cancer – Pipeline by Bristol-Myers Squibb Co
      • Celgene Corp
        • Table Bladder Cancer – Pipeline by Celgene Corp
      • Celldex Therapeutics Inc
        • Table Bladder Cancer – Pipeline by Celldex Therapeutics Inc
      • Celprogen Inc
        • Table Bladder Cancer – Pipeline by Celprogen Inc
      • Celsion Corp
        • Table Bladder Cancer – Pipeline by Celsion Corp
      • Celyad SA
        • Table Bladder Cancer – Pipeline by Celyad SA
      • Cleveland BioLabs Inc
        • Table Bladder Cancer – Pipeline by Cleveland BioLabs Inc
      • Cold Genesys Inc
        • Table Bladder Cancer – Pipeline by Cold Genesys Inc
      • Corvus Pharmaceuticals Inc
        • Table Bladder Cancer – Pipeline by Corvus Pharmaceuticals Inc
      • CytomX Therapeutics Inc
        • Table Bladder Cancer – Pipeline by CytomX Therapeutics Inc
      • Cytori Therapeutics Inc
        • Table Bladder Cancer – Pipeline by Cytori Therapeutics Inc
      • Daiichi Sankyo Co Ltd
        • Table Bladder Cancer – Pipeline by Daiichi Sankyo Co Ltd
      • Eisai Co Ltd
        • Table Bladder Cancer – Pipeline by Eisai Co Ltd
      • Eleven Biotherapeutics Inc
        • Table Bladder Cancer – Pipeline by Eleven Biotherapeutics Inc
      • Eli Lilly and Co
        • Table Bladder Cancer – Pipeline by Eli Lilly and Co
      • Elsalys Biotech SAS
        • Table Bladder Cancer – Pipeline by Elsalys Biotech SAS
      • EpiThany Inc
        • Table Bladder Cancer – Pipeline by EpiThany Inc
      • Esperance Pharmaceuticals Inc
        • Table Bladder Cancer – Pipeline by Esperance Pharmaceuticals Inc
      • Exelixis Inc
        • Table Bladder Cancer – Pipeline by Exelixis Inc
      • Exicure Inc
        • Table Bladder Cancer – Pipeline by Exicure Inc
      • F. Hoffmann-La Roche Ltd
        • Table Bladder Cancer – Pipeline by F. Hoffmann-La Roche Ltd
      • Five Prime Therapeutics Inc
        • Table Bladder Cancer – Pipeline by Five Prime Therapeutics Inc
      • Gene Signal International SA
        • Table Bladder Cancer – Pipeline by Gene Signal International SA
      • Genentech Inc
        • Table Bladder Cancer – Pipeline by Genentech Inc
      • Genmab A/S
        • Table Bladder Cancer – Pipeline by Genmab A/S
      • GlaxoSmithKline Plc
        • Table Bladder Cancer – Pipeline by GlaxoSmithKline Plc
      • H3 Biomedicine Inc
        • Table Bladder Cancer – Pipeline by H3 Biomedicine Inc
      • Hamlet Pharma AB
        • Table Bladder Cancer – Pipeline by Hamlet Pharma AB
      • Hanmi Pharmaceuticals Co Ltd
        • Table Bladder Cancer – Pipeline by Hanmi Pharmaceuticals Co Ltd
      • HitGen LTD
        • Table Bladder Cancer – Pipeline by HitGen LTD
      • Horizon Pharma Plc
        • Table Bladder Cancer – Pipeline by Horizon Pharma Plc
      • Immunocore Ltd
        • Table Bladder Cancer – Pipeline by Immunocore Ltd
      • Immunomedics Inc
        • Table Bladder Cancer – Pipeline by Immunomedics Inc
      • Immupharma Plc
        • Table Bladder Cancer – Pipeline by Immupharma Plc
      • Imugene Ltd
        • Table Bladder Cancer – Pipeline by Imugene Ltd
      • Incanthera Ltd
        • Table Bladder Cancer – Pipeline by Incanthera Ltd
      • Incyte Corp
        • Table Bladder Cancer – Pipeline by Incyte Corp
      • Innovation Pharmaceuticals Inc
        • Table Bladder Cancer – Pipeline by Innovation Pharmaceuticals Inc
      • InteRNA Technologies BV
        • Table Bladder Cancer – Pipeline by InteRNA Technologies BV
      • Iovance Biotherapeutics Inc
        • Table Bladder Cancer – Pipeline by Iovance Biotherapeutics Inc
      • Johnson & Johnson
        • Table Bladder Cancer – Pipeline by Johnson & Johnson
      • Kite Pharma Inc
        • Table Bladder Cancer – Pipeline by Kite Pharma Inc
      • Laboratoires Pierre Fabre SA
        • Table Bladder Cancer – Pipeline by Laboratoires Pierre Fabre SA
      • LipoMedix Pharmaceutical Inc
        • Table Bladder Cancer – Pipeline by LipoMedix Pharmaceutical Inc
      • Loxo Oncology Inc
        • Table Bladder Cancer – Pipeline by Loxo Oncology Inc
      • Lycera Corp
        • Table Bladder Cancer – Pipeline by Lycera Corp
      • MacroGenics Inc
        • Table Bladder Cancer – Pipeline by MacroGenics Inc
      • Marina Biotech Inc
        • Table Bladder Cancer – Pipeline by Marina Biotech Inc
      • MaxiVAX SA
        • Table Bladder Cancer – Pipeline by MaxiVAX SA
      • Medicenna Therapeutics Corp
        • Table Bladder Cancer – Pipeline by Medicenna Therapeutics Corp
      • MedImmune LLC
        • Table Bladder Cancer – Pipeline by MedImmune LLC
      • Merck & Co Inc
        • Table Bladder Cancer – Pipeline by Merck & Co Inc
      • Merck KGaA
        • Table Bladder Cancer – Pipeline by Merck KGaA
      • Mirati Therapeutics Inc
        • Table Bladder Cancer – Pipeline by Mirati Therapeutics Inc
      • Moleculin Biotech Inc
        • Table Bladder Cancer – Pipeline by Moleculin Biotech Inc
      • MTG Biotherapeutics Inc
        • Table Bladder Cancer – Pipeline by MTG Biotherapeutics Inc
      • NanoCarrier Co Ltd
        • Table Bladder Cancer – Pipeline by NanoCarrier Co Ltd
      • NantKwest Inc
        • Table Bladder Cancer – Pipeline by NantKwest Inc
      • Nektar Therapeutics
        • Table Bladder Cancer – Pipeline by Nektar Therapeutics
      • Novartis AG
        • Table Bladder Cancer – Pipeline by Novartis AG
      • OncoTherapy Science Inc
        • Table Bladder Cancer – Pipeline by OncoTherapy Science Inc
      • Oncovir Inc
        • Table Bladder Cancer – Pipeline by Oncovir Inc
      • Ono Pharmaceutical Co Ltd
        • Table Bladder Cancer – Pipeline by Ono Pharmaceutical Co Ltd
      • Optimum Therapeutics LLC
        • Table Bladder Cancer – Pipeline by Optimum Therapeutics LLC
      • Oxford BioTherapeutics Ltd
        • Table Bladder Cancer – Pipeline by Oxford BioTherapeutics Ltd
      • Pfizer Inc
        • Table Bladder Cancer – Pipeline by Pfizer Inc
      • Pharma Mar SA
        • Table Bladder Cancer – Pipeline by Pharma Mar SA
      • Philogen SpA
        • Table Bladder Cancer – Pipeline by Philogen SpA
      • Pieris Pharmaceuticals Inc
        • Table Bladder Cancer – Pipeline by Pieris Pharmaceuticals Inc
      • Plexxikon Inc
        • Table Bladder Cancer – Pipeline by Plexxikon Inc
      • Polaris Pharmaceuticals Inc
        • Table Bladder Cancer – Pipeline by Polaris Pharmaceuticals Inc
      • Provecs Medical GmbH (Inactive)
        • Table Bladder Cancer – Pipeline by Provecs Medical GmbH (Inactive)
      • Provectus Biopharmaceuticals Inc
        • Table Bladder Cancer – Pipeline by Provectus Biopharmaceuticals Inc
      • PsiOxus Therapeutics Ltd
        • Table Bladder Cancer – Pipeline by PsiOxus Therapeutics Ltd
      • Rexahn Pharmaceuticals Inc
        • Table Bladder Cancer – Pipeline by Rexahn Pharmaceuticals Inc
      • Samyang Holdings Corp
        • Table Bladder Cancer – Pipeline by Samyang Holdings Corp
      • Sanofi
        • Table Bladder Cancer – Pipeline by Sanofi
      • Sareum Holdings Plc
        • Table Bladder Cancer – Pipeline by Sareum Holdings Plc
      • Shionogi & Co Ltd
        • Table Bladder Cancer – Pipeline by Shionogi & Co Ltd
      • Sierra Oncology Inc
        • Table Bladder Cancer – Pipeline by Sierra Oncology Inc
      • Sillajen Biotherapeutics
        • Table Bladder Cancer – Pipeline by Sillajen Biotherapeutics
      • Sitka Biopharma Inc
        • Table Bladder Cancer – Pipeline by Sitka Biopharma Inc
      • Sorrento Therapeutics Inc
        • Table Bladder Cancer – Pipeline by Sorrento Therapeutics Inc
      • Spectrum Pharmaceuticals Inc
        • Table Bladder Cancer – Pipeline by Spectrum Pharmaceuticals Inc
      • Stemline Therapeutics Inc
        • Table Bladder Cancer – Pipeline by Stemline Therapeutics Inc
      • Sun Pharma Advanced Research Company Ltd
        • Table Bladder Cancer – Pipeline by Sun Pharma Advanced Research Company Ltd
      • Taiwan Liposome Company Ltd
        • Table Bladder Cancer – Pipeline by Taiwan Liposome Company Ltd
      • Taris Biomedical LLC
        • Table Bladder Cancer – Pipeline by Taris Biomedical LLC
      • Theralase Technologies Inc
        • Table Bladder Cancer – Pipeline by Theralase Technologies Inc
      • Tocagen Inc
        • Table Bladder Cancer – Pipeline by Tocagen Inc
      • Tolero Pharmaceuticals Inc
        • Table Bladder Cancer – Pipeline by Tolero Pharmaceuticals Inc
      • Transgene SA
        • Table Bladder Cancer – Pipeline by Transgene SA
      • UroGen Pharma Ltd
        • Table Bladder Cancer – Pipeline by UroGen Pharma Ltd
      • Vaccibody AS
        • Table Bladder Cancer – Pipeline by Vaccibody AS
      • Vakzine Projekt Management GmbH
        • Table Bladder Cancer – Pipeline by Vakzine Projekt Management GmbH
      • Vault Pharma Inc
        • Table Bladder Cancer – Pipeline by Vault Pharma Inc
      • Vaxeal Holding SA
        • Table Bladder Cancer – Pipeline by Vaxeal Holding SA
      • Vaxiion Therapeutics Inc
        • Table Bladder Cancer – Pipeline by Vaxiion Therapeutics Inc
      • Viralytics Ltd
        • Table Bladder Cancer – Pipeline by Viralytics Ltd
      • Vyriad Inc
        • Table Bladder Cancer – Pipeline by Vyriad Inc
      • Zymeworks Inc
        • Table Bladder Cancer – Pipeline by Zymeworks Inc
  • Dormant Projects
    • Bladder Cancer
      • Table Bladder Cancer – Dormant Projects
  • Discontinued Products
    • Bladder Cancer
      • Table Bladder Cancer – Discontinued Products
  • Product Development Milestones
    • Ureter Cancer
      • Featured News & Press Releases
    • Bladder Cancer
      • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report